is expressed on activated T lymphocytes3 and the interaction of CD40 with its ligand appears to be critical for normal B lymphocyte differentiation and development. Antibodies to CD40 have also been shown to promote normal human Bcell proliferation in vitro when given with IL-44 and to induce the secretion of Ig.5*6 We and others7"' have observed in both B-and T-cell malignancies that antitumor effects (growth arrest with or without apoptosis) often result when malignant cells are exposed to stimuli that lead to activation of normal lymphocytes. This activation-induced growth arrest has been observed with signals through either antigen receptors or costimulatory receptors."" Because anti-CD40 exerts growth-promoting effects on normal human B cells, we wanted to determine the effects of anti-CD40 on the growth of various human B-cell lymphomas both in vitro and in vivo. We report here that CD40 stimulation is capable of inhibiting the growth of several B-cell lymphomas and inducing regression of established tumors in vivo.
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C MATERIALS AND METHODS
Mice. C.B-17 severe combined immune deficiency (SCID) mice were obtained from the Animal Production Facility (National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD) and were not used until 6 to 8 weeks of age. SCID mice were kept under specific-pathogen-free conditions at all times. The mice were housed in microisolator cages and all food, water, and bedding were autoclaved before use. SCID mice received trimethoprim/sulfamethoxazole (40 mg trimethoprim and 200 mg sulfamethoxazole per 320 mL drinking water) in suspension in their drinking water.
Antibodies. Antihuman CD40 (m2 and m3 hybridomas, mouse IgGl antibody) was provided by Immunex (Seattle, WA). These antibodies have been shown to be specific for CD40 and exerted costimulatory responses on human B-cell proliferation." Mouse IgGl myeloma protein was purchased from Cappel (West Chester, PA). These lymphomas were kept in culture for no more than 6 months before the study. Raji is a cell line cultured from a patient with Burkitt's lymphoma."
In vivo experiments. All mice received 20 pL of anti-asialo GM1 (crASGM1) (Wako Chemicals, Dallas, TX) by intravenous (IV) injection 1 day before tumor transfer to remove host natural killer cells.14 RL, TU2C, or Raji tumor cells (5 X lo6) were then administered either by IV or intraperitoneal (IP) injection. SCID recipients then received either 2 pg of anti-CD40 or mouse IgGl myeloma protein in 0.2 mL Hanks' Balanced Salt Solution (HBSS) IP every other day for 20 days for a total of 10 injections starting at day 0, 3, or 14. This dose of anti-CD40 was initially used because of the limited amount of reagent available for in vivo studies. Tumorbearing mice were then monitored for tumor development and progression. Moribund mice were killed. All mice were necropsied for evidence of tumor. Liver, kidney, and lymphoid organs were analyzed histologically for presence of tumor. Both parametric (Student's t-test) and nonparametric (Wilcoxon rank-sum test) analyses were performed to determine if the groups differed significantly (P < .05). All experiments had 3 to 10 mice per group and were performed two to three times.
Immunojuorescence studies. Proliferation assay. The effect of anti-CD40 on B-cell lymphoma growth in vitro was determined by [3H]-thymidine incorporation." The cell lines were split 24 hours before assays were performed. Cells were resuspended in culture medium to a concentration of 1 X 105/mL, and 100 pL was plated in 96-well flat-bottom microtiter plates (Coming Glass Works, Coming, NY) already containing 100 pL of appropriately diluted reagents of anti-CD40, M2, and M3 clones (Immunex) or mouse IgG myeloma protein (Cappel). Seventy-two hours later, 1 pCi of [3H]-thymidine/well (specific activity, 6.7 Ci/mmol; [New England Nuclear Research Products, Boston, MA]) was added for the final 8 to 18 hours to culture. Cultures were harvested onto glass fiber filters with a PhD Cell Harvesting System (Cambridge Technology, Inc, Cambridge, MA), and [3H]-thymidine uptake was assayed by liquid scintillation on an LKB betacounter (LKB Instruments, Inc, Turku, Finland). Each experiment was performed four to six times with a representative experiment being shown. Counts per minute (CPM) were analyzed, untransformed, by regression analysis and analysis of variance. A linear relationship between CPM level and the logarithm of the concentration was assumed. When no significant departure from linearity was detected, the regression slopes for the control and treated samples were compared by r-test. For the experiments involving prior crosslinking, 100 pL of goat-antimouse IgG (Fisher-Science, Pittsburgh, PA) at a concentration of 25 pg/mL was added into the wells and incubated for 24 hours. The wells were incubated overnight at 37°C with goat-antimouse IgG antibody. After washing with HBSS twice, some wells then received anti-CD40 or msIgG at 10 pg/mL and were allowed to incubate for 2 hours. The tumor cells were then added and the proliferation assay was then performed as described earlier. For determination of the effects of soluble human CD40 ligand, RL or TU2C cell lines were incubated with either titrations of COS-7 control supernatants or COS-7 supernatants containing soluble human CD40 ligand (supplied by Immunex). The recombinant soluble human CD40 ligand has been shown to induce the proliferation of human B cells in vitro." Values are reflected as percent inhibition of proliferation in comparison to control supematants.
RESULTS
Su$ace expression of CD40 on various human B-cell lymphomas. We first examined the cell surface expression of CD40 in RL and TU2C cell lines by immunofluorescence and flow cytometric analysis. Both lymphomas showed surface expression of CD40 molecules, although to varying degrees (Fig 1) . The RL tumor line that was isolated from a patient with diffuse large cell lymphoma was relatively homogeneous for CD40 expression as indicated by immunofluorescence and the narrow peak of positive cells in the flow cytometric analysis (Fig 1A and inset) . The EBV-induced lymphoma line TU2C, obtained from a huPBL-SCID chimeric mouse, had a broader range of CD40 expression with very bright and dim cells present (Fig 1B and inset) . EBVinduced B-cell lymphomas derived from SCID mice have previously been shown to be heterogeneous and oligoclonal'' (and unpublished data, February 1992) and this may account for the differential expression of CD40 in these tumors. Similar results were obtained through the examination of other EBV-induced B-cell lymphoma lines with respect to CD40 expression (data not shown). We then ascertained the effects of soluble anti-CD40 antibodies on the proliferative potential of these various B-cell lymphomas in vitro.
EfSects of anti-CD40 on human B-cell lymphoma proliferation in vitro. Incubation with anti-CD40 significantly inhibited the proliferation of R L , DB, TU2C, and CHIM62 cell lines tested with an optimal inhibition of thymidine incorporation (of 40% to 60%) occurring at 1 to 10 pg/mL of soluble antibody depending on the lymphoma when compared with isotype-matched control antibody (Fig 2, A-D) . No inhibitory effects of soluble anti-CD40 were detected on the Raji cell line (Fig 2E) . We have found that 10 to 100 pg of anti-CD40 are saturating amounts in this assay. The effects of soluble anti-CD40 antibody were then compared with those of immobilized anti-CD40 on lymphoma growth to determine if cross-linking the antibody would result in greater inhibition. The data show that cross-linking the antibody results in significantly ( P < .001) greater growth inhibition of the RL lymphoma cell line (Fig 3A) . Thus, anti-CD40 appears to directly inhibit human B-cell lymphoma proliferation in vitro and cross-linking appears to augment the inhibitory signals. We found that soluble anti-CD40 had no effect on the proliferation of Burkitt's lymphoma (Raji) cells (Fig 2E) . This is in agreement with previous reports that detected no effect of CD40 stimulation on Burkitt's lymphoma cell lines.17 However, if anti-CD40 was crosslinked, significant ( P < .001) inhibition could now be detected (Fig 3B) indicating that CD40 stimulation is also capable of inhibiting the proliferation of Burkitt's lymphoma cell lines. These results show that the in vitro assay conditions are critical in evaluating the effects of anti-CD40 on B-cell lymphoma growth and that anti-CD40 appears capable of providing inhibitory signals to a variety of B-cell lymphomas. lymphomas tested with maximal inhibition seen (50% to 80%) on RL and TU2C cell lines at a 1 5 dilution of the supernatant (Fig 4) . The soluble murine CD40 ligand, which is active on both murine and human B cells, produced similar inhibitory effects on lymphoma proliferation (data not shown). Thus, in contrast with its effects on normal B cells, stimulation of CD40 by either antibody or its ligand exerts inhibitory effects on neoplastic B cells. Antitumor effects of anti-CD40 treatment in SCID mice bearing human B-cell lymphomas. We then determined if anti-CD40 would be efficacious in the treatment of these lymphomas in vivo. SCID mice bearing either I U or TU2C lymphomas were treated at various times with anti-CD40. All mice received antisera to asialo GM1, a marker present on murine NK cells, before cell transfer to remove host resistance to the tumor.14 Significant (P < .01) increases in survival in SCID mice receiving either RL or TU2C Bcell lymphomas were noted in the recipients receiving 2-pg injections of anti-CD40 given every other day for a total of 10 injections starting on day 0 (Table 1) . Recipient mice received the human lymphomas either by IP or IV injection, resulting in differential patterns of metastatic growth. Mice receiving the EBV-induced lymphomas by IP injection developed peritoneal tumors with extensive metastases in the lymph nodes and liver, whereas mice receiving the lymphomas by IV injection primarily developed renal metastases (data not shown). Treatment with anti-CD40 was capable of significantly inhibiting tumor growth and promoting survival of recipient mice regardless of the route of tumor inoculation (Table 1) . No overt toxicity was detected after repeated administration of anti-CD40 in the recipients as determined by necropsy of the surviving mice. Treatment with anti-CD40 of SCID mice bearing a human melanoma that was negative for CD40 resulted in no differences in tumor growth and no effects on survival (data not shown). Treatment with anti-CD40 of SCID mice injected with RL tumor cells also resulted in significantly (P < .01) improved survival when the treatment was initiated 3 or 14 days after tumor cell transfer (Fig 5) . These results indicate that anti-CD40 treatment was also efficacious when treatment was initiated with relatively large tumor burdens (> 1 cm') in the recipient mice. Addi- (day 3)
Effects of soluble CD40 ligand on human B-cell lymphoma
T U X (IV) Anti-CD40 6 38 2 2.6 * SClD mice were treated as described in Materials and Methods.
All mice received anti-ASGM1 IV 1 day before tumor transfer. On the day antibody treatment was initiated, they received either mslgG control or anti-CD40 (2 pg IP administered every other day for a total of 10 injections). All experiments were performed two or three times with five to seven mice per group. Anti-CD40 treatment significantly ( P < .01) improved survival of mice receiving either RL or T U X tumors when treatment was initiated on day 0 or day 3. t Three of six mice showed no evidence of tumor.
* One of six mice showed no evidence of tumor.
tionally, administration of anti-CD40 resulted in a significant ( P C= .01) increase in survival of recipients receiving Raji tumor cells (Fig 6) . Thus, anti-CD40 treatment is efficacious for a variety of human B-cell lymphomas in vivo. Studies are currently underway to evaluate the recombinant soluble human CD40 ligand in the treatment of tumor-bearing mice.
DISCUSSION
We report here that CD40 stimulation directly inhibits the proliferation of various human B-cell lymphomas in vitro t " and is efficacious against a wide variety of B-cell lymphomas in vivo. This is the first report showing that CD40 stimulation can provide negative signals to a variety of transformed B lymphocytes. Previous reports concerning CD40 have focused on its ability to promote B-cell growth and prevent a p o p t~s i s .~~~~" Indeed, there have been reports that CD40 stimulation does not inhibit the growth of Burkitt's lymphomas and promotes the proliferation of follicular cell lymphoma~.".'~ However, all of the previous studies used soluble CD40 antibodies with the tumor cells in vitro. We show that cross-linking markedly enhances the inhibitory signals of anti-CD40 (Fig 3) and this may account for the lack of inhibition reported by other investigators. We also observed, in agreement with the previously mentioned reports, that a Burkitt's lymphoma cell line was not significantly inhibited by soluble anti-CD40 (Fig 3B) . However, immobilized anti-CD40 does inhibit the growth of these cells in vitro and anti-CD40 significantly increases survival in mice bearing these tumors (Fig 6) . Prior cross-linking of anti-IgM antibodies has also been shown to markedly enhance the inhibitory effects of surface Ig binding on B-cell lymphoma^'^^'^ and it appears that CD40 also needs to be cross-linked for optimal inhibition. This implies that signal transduction is required to mediate the observed effects. Preliminary evidence indicates, at least with the EBV-induced lymphoma line TU2C, that anti-CD40 is capable of inducing apoptosis. However, some lymphomas undergo irreversible growth arrest without apoptosis in vitro.
Because anti-CD40 or soluble CD40 ligand can inhibit various B-cell lymphomas directly, it may not be necessary to use it as an immunotoxin or a radioimmunoconjugate, thus avoiding toxicities associated with toxins and nuclides For personal use only. on September 24, 2017. by guest www.bloodjournal.org From and potentially negative effects on normal B cells. Use of the soluble human CD40 ligand is especially attractive because no human-antimouse antibodies would be elicited that would neutralize the antitumor effects. Thus, long-term exposure to CD40 ligand is theoretically possible. Furthermore, the selective effects of anti-CD40 on B cells makes it attractive in settings where cytotoxic therapy may be too toxic (eg, acquired immune deficiency syndrome patients, elderly patients, and posttransplant patients).
It is of interest that treatment of mice bearing the RL lymphoma with anti-CD40 resulted in mice showing no evidence of disease for at least 100 days. By contrast, statistically significant but modest inhibition of RL proliferation was noted when the lymphoma was incubated with soluble anti-CD40 in vitro (Fig 2A, Table 1 ). This also suggests that there may be additional yet-undefined antitumor mechanisms by which anti-CD40 can exert its effects when given in vivo. It may be that better cross-linking of the antibody is achieved in vivo as opposed to soluble antibody exposure in vitro because we have shown that greater inhibition of proliferation is obtained in vitro with immobilized anti-CD40 (Fig   3) . Alternatively, it may be that antibody-dependent cellmediated cytotoxicity may be contributing to the responses seen in vivo. In support of this, it has been reported that treatment of SCID mice bearing human EBV-induced B-cell lymphomas with nonconjugated CD21, CD23, and CD24 monoclonal antibodies could prolong their survival.2o It was reported that these antibodies did not inhibit the growth of these lymphomas in vitro, so the in vivo mechanism remains speculative although ADCC may be responsible. Studies are currently underway to compare the efficacy of anti-CD40 with these and other B-cell lymphoma surface markers. The data also show that anti-CD40 treatment is more efficacious if the lymphoma is also administered by IP as opposed to IV innoculation (Table l, Fig 4) . This may simply be caused by the fact that, because the antibody is administered by IP injection, this would allow for higher concentrations of the antibody to be present at the sites of tumor.
It would also be important to determine if anti-CD40 treatment selectively inhibits tumor cell growth while at the same time sparing normal B cells. We have data showing that anti-CD40 prevents human B-cell lymphomagenesis in the huPBL-SCID chimeric mouse model and at the same time promotes human B-cell engraftment in vivo (Murphy et al, manuscript submitted). This would suggest that use of anti-CD40 would be advantageous because of its selectivity for inhibiting transformed cells.
The CD40 molecule is in the tumor necrosis factorherve growth factor receptor family that also includes CD30 and Fas.2'.22 It has been speculated that because Fas is involved in the induction of apoptosis that Fas stimulation may be applicable in the treatment of EBV-lymph~mas.'~ However, treatment of mice with anti-Fas antibodies resulted in death because of extremely toxic effects on the liver.24 Because CD40 expression appears restricted to B cells and monocytes," little toxicity should occur after in vivo administration. Additionally, CD40 has also been detected on some carcinomas and melanomas'; it will be of considerable interest to examine the effects of anti-CD40 on the growth of these tumors.
Thus, stimulation of CD40 by either antibody or its ligand molecules may offer a biologic approach to the treatment of human B-cell lymphomas.
